C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals

Christopher D. Nishimura, Daniel A. Brenner, Malini Mukherjee, Rachel A. Hirsch, Leah Ott, Meng Fen Wu, Hao Liu, Olga Dakhova, Jordan S. Orange, Malcolm K. Brenner, Charles Y. Lin, Caroline Arber

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired. Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. Thus, we hypothesized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-engineered TCR-Transgenic T cells. We found that c-MPL1 polyclonal T cells expand and proliferate in response to TPO, and persist longer after adoptive transfer in immunodeficient human TPO-Transgenic mice. In TCR-Transgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine production and preserves a central memory phenotype. c-MPL signaling also enables sequential tumor cell killing, enhances the formation of effective immune synapses, and improves antileukemic activity in vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced transgenic T cells responding to either endogenously produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-Targeted pharmacological agents.

Original languageEnglish (US)
Pages (from-to)2739-2749
Number of pages11
JournalBlood
Volume130
Issue number25
DOIs
StatePublished - Dec 21 2017
Externally publishedYes

Fingerprint

Thrombopoietin Receptors
Adoptive Immunotherapy
Interferon Type I
T-Cell Antigen Receptor
Heterografts
Signal Transduction
Cell Proliferation
Cytokines
T-Lymphocytes
Thrombopoietin
Neoplasms
Leukemia
Colony-Stimulating Factor Receptors
Pharmacology
Cytokine Receptors
Tumor Microenvironment
Adoptive Transfer
Hematologic Neoplasms
United States Food and Drug Administration
Transgenes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nishimura, C. D., Brenner, D. A., Mukherjee, M., Hirsch, R. A., Ott, L., Wu, M. F., ... Arber, C. (2017). C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals. Blood, 130(25), 2739-2749. https://doi.org/10.1182/blood-2017-02-769463

C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals. / Nishimura, Christopher D.; Brenner, Daniel A.; Mukherjee, Malini; Hirsch, Rachel A.; Ott, Leah; Wu, Meng Fen; Liu, Hao; Dakhova, Olga; Orange, Jordan S.; Brenner, Malcolm K.; Lin, Charles Y.; Arber, Caroline.

In: Blood, Vol. 130, No. 25, 21.12.2017, p. 2739-2749.

Research output: Contribution to journalArticle

Nishimura, CD, Brenner, DA, Mukherjee, M, Hirsch, RA, Ott, L, Wu, MF, Liu, H, Dakhova, O, Orange, JS, Brenner, MK, Lin, CY & Arber, C 2017, 'C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals', Blood, vol. 130, no. 25, pp. 2739-2749. https://doi.org/10.1182/blood-2017-02-769463
Nishimura CD, Brenner DA, Mukherjee M, Hirsch RA, Ott L, Wu MF et al. C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals. Blood. 2017 Dec 21;130(25):2739-2749. https://doi.org/10.1182/blood-2017-02-769463
Nishimura, Christopher D. ; Brenner, Daniel A. ; Mukherjee, Malini ; Hirsch, Rachel A. ; Ott, Leah ; Wu, Meng Fen ; Liu, Hao ; Dakhova, Olga ; Orange, Jordan S. ; Brenner, Malcolm K. ; Lin, Charles Y. ; Arber, Caroline. / C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals. In: Blood. 2017 ; Vol. 130, No. 25. pp. 2739-2749.
@article{da86a72d826a4ad8bb239a3a306df94c,
title = "C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals",
abstract = "Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired. Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. Thus, we hypothesized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-engineered TCR-Transgenic T cells. We found that c-MPL1 polyclonal T cells expand and proliferate in response to TPO, and persist longer after adoptive transfer in immunodeficient human TPO-Transgenic mice. In TCR-Transgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine production and preserves a central memory phenotype. c-MPL signaling also enables sequential tumor cell killing, enhances the formation of effective immune synapses, and improves antileukemic activity in vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced transgenic T cells responding to either endogenously produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-Targeted pharmacological agents.",
author = "Nishimura, {Christopher D.} and Brenner, {Daniel A.} and Malini Mukherjee and Hirsch, {Rachel A.} and Leah Ott and Wu, {Meng Fen} and Hao Liu and Olga Dakhova and Orange, {Jordan S.} and Brenner, {Malcolm K.} and Lin, {Charles Y.} and Caroline Arber",
year = "2017",
month = "12",
day = "21",
doi = "10.1182/blood-2017-02-769463",
language = "English (US)",
volume = "130",
pages = "2739--2749",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals

AU - Nishimura, Christopher D.

AU - Brenner, Daniel A.

AU - Mukherjee, Malini

AU - Hirsch, Rachel A.

AU - Ott, Leah

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Dakhova, Olga

AU - Orange, Jordan S.

AU - Brenner, Malcolm K.

AU - Lin, Charles Y.

AU - Arber, Caroline

PY - 2017/12/21

Y1 - 2017/12/21

N2 - Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired. Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. Thus, we hypothesized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-engineered TCR-Transgenic T cells. We found that c-MPL1 polyclonal T cells expand and proliferate in response to TPO, and persist longer after adoptive transfer in immunodeficient human TPO-Transgenic mice. In TCR-Transgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine production and preserves a central memory phenotype. c-MPL signaling also enables sequential tumor cell killing, enhances the formation of effective immune synapses, and improves antileukemic activity in vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced transgenic T cells responding to either endogenously produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-Targeted pharmacological agents.

AB - Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired. Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. Thus, we hypothesized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-engineered TCR-Transgenic T cells. We found that c-MPL1 polyclonal T cells expand and proliferate in response to TPO, and persist longer after adoptive transfer in immunodeficient human TPO-Transgenic mice. In TCR-Transgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine production and preserves a central memory phenotype. c-MPL signaling also enables sequential tumor cell killing, enhances the formation of effective immune synapses, and improves antileukemic activity in vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced transgenic T cells responding to either endogenously produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-Targeted pharmacological agents.

UR - http://www.scopus.com/inward/record.url?scp=85039153675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039153675&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-02-769463

DO - 10.1182/blood-2017-02-769463

M3 - Article

VL - 130

SP - 2739

EP - 2749

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -